News

Public · Published

Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting

Werewolf Therapeutics announced it was selected for an oral presentation and will present two posters at the Society for Immunotherapy of Cancer's 2026 Annual Meeting, held November 4-8, 2026, in Phoenix, Arizona. The oral presentation covers a Phase 1/1b study of WTX-124 alone or with pembrolizumab.

Published:

Updated:

What happened

Werewolf Therapeutics announced it was selected for an oral presentation and will present two posters at the Society for Immunotherapy of Cancer's 2026 Annual Meeting, held November 4-8, 2026, in Phoenix, Arizona. The oral presentation covers a Phase 1/1b study of WTX-124 alone or with pembrolizumab.

Confirmed

Global impact / market context

Presenting clinical trial data at a major cancer conference gives a small biopharmaceutical company a public stage to show how its tumor-activated treatments perform in patients. Positive or negative findings can shape how doctors, partners, and investors view the company's pipeline and its ability to raise future funding.

Analyst inference

Investors in early-stage biopharmaceutical companies often treat conference presentations as catalysts because they reveal new clinical data that was not previously public. For Werewolf, the oral slot and two posters put its WTX-124 and WTX-330 programs in front of specialists, which may influence expectations about timelines and partnering prospects.

Analyst inference

What to watch

  1. The oral presentation on WTX-124 is scheduled for Saturday, November 7, 2026, from 2:30 to 2:45 p.m. MT, in the North Building, 300 Level, Halls BC. Confirmed
  2. The poster on WTX-330 is scheduled for Saturday, November 7, 2026, from 9 a.m. to 8:30 p.m. MT, in the North Building, Lower Level, Exhibition Halls 4-6. Confirmed
  3. Watch whether the presented trial results show encouraging safety and response signals for these tumor-activated treatments, since such findings could affect investor views on the company's pipeline and future funding needs. Analyst inference

Evidence